Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) has announced an upcoming investor event scheduled for December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66th American Society of Hematology Annual Meeting in San Diego. The event will be held both in-person and via webcast.

The company's management team will collaborate with key opinion leaders to present updates on their revumenib and Niktimvo™ (axatilimab-csfr) programs. Interested parties can access the live webcast through the Investor section of Syndax's website, where a recording will also be available temporarily.

News Market Reaction – SNDX

+3.96%

+3.96% Session move

In the trading session that priced this news, SNDX gained 3.96%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66^th American Society of Hematology (ASH) Annual Meeting in San Diego, California. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company's revumenib and Niktimvo™ (axatilimab-csfr) programs.

A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-host-ash-investor-event-in-person-and-via-webcast-on-december-9-2024-302295973.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When is Syndax's (SNDX) ASH investor event scheduled for 2024?

Syndax's ASH investor event is scheduled for Monday, December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET in San Diego, California.

What programs will be discussed at Syndax's (SNDX) December 2024 investor event?

The event will feature updates on Syndax's revumenib and Niktimvo™ (axatilimab-csfr) programs.

How can investors access Syndax's (SNDX) ASH 2024 investor event?

Investors can attend either in person in San Diego or via live webcast through the Investor section of Syndax's website at www.syndax.com.

Where will Syndax's (SNDX) December 2024 investor event be held?

The event will be held during the 66th American Society of Hematology Annual Meeting in San Diego, California.